Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 4/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | CPA1 | P15085 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 3/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5841678 | 1.00 | MME (0.47) | MMEACECPA1ACE2PDCD1LG2 | |
| SCHEMBL23030200 | 1.00 | MME (0.47) | MMEACECPA1ACE2PDCD1LG2 | |
| SCHEMBL29531322 | 1.00 | MME (0.47) | MMEACECPA1ACE2PDCD1LG2 | |
| SCHEMBL30781147 | 1.00 | MME (0.47) | MMEACECPA1ACE2PDCD1LG2 | |
| SCHEMBL29630637 | 0.96 | MME (0.44) | MMEACECPA1ACE2PDCD1LG2 | |
| SCHEMBL29462560 | 0.96 | MME (0.44) | MMEACECPA1ACE2PDCD1LG2 | |
| SCHEMBL30552861 | 0.91 | MME (0.41) | MMEACECPA1ACE2PDCD1LG2 | |
| SCHEMBL30118062 | 0.89 | BACE1 (0.44) | MMEACECPA1ACE2PDCD1LG2 | |
| SCHEMBL30974446 | 0.88 | PDCD1LG2 (0.48) | MMEACECPA1ACE2PDCD1LG2 | |
| SCHEMBL30123047 | 0.88 | PDCD1LG2 (0.48) | MMEACECPA1ACE2PDCD1LG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263437-A1 | POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF | SICHUAN GOODDOCTOR PANXI PHARMACEUTICAL CO., LTD. (CN) | 2025-08-21 | — | — | US | claimed |
| EP-4276105-A1 | POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF | Sichuan Gooddoctor Panxi Pharmaceutical Co. Ltd (CN) | 2023-11-15 | — | — | EP | claimed |
| CN-114262362-B | EphA2 receptor targeting 68 Ga-NODAGA-cyclic polypeptide FG01, preparation method and application | 齐鲁工业大学 | 2023-05-26 | — | — | CN | claimed |
| CN-114805489-A | Polypeptide for repairing skin injury or mucous membrane injury and application thereof | 四川好医生攀西药业有限责任公司 | 2022-07-29 | — | — | CN | claimed |
| WO-2022148289-A1 | POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF | 四川好医生攀西药业有限责任公司 | 2022-07-14 | — | — | WO | claimed |
| EP-4713008-A2 | METHODS FOR ELICITING AN IMMUNE RESPONSE TO RESPIRATORY SYNCYCIAL VIRUS AND STREPTOCOCCUS PNEUMONIAE INFECTION | GlaxoSmithKline Biologicals S.A. (BE) | 2026-03-25 | — | — | EP | disclosed |
| US-20260078178-A1 | METHODS AND COMPOSITIONS FOR INCREASING IDURONATE 2-SULFATASE ACTIVITY IN THE CNS | ARMAGEN INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260062499-A1 | Compositions and Methods of Inhibiting MASP-2 for the Treatment of Various Thrombotic Diseases and Disorders | OMEROS CORP (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260062498-A1 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | OMEROS CORP (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260049158-A1 | Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and Disorders | OMEROS CORP (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4695412-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | Ohio State Innovation Foundation (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260035483-A1 | Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and Disorders | OMEROS CORP (US) | 2026-02-05 | — | — | US | disclosed |
| EP-3964233-A1 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | University Of Leicester (GB) | 2022-03-09 | — | — | EP | disclosed |
| US-20220064330-A1 | METHODS FOR TREATING AND/OR PREVENTING IDIOPATHIC PNEUMONIA SYNDROME (IPS) AND/OR CAPILLARY LEAK SYNDROME (CLS) AND/OR ENGRAFTMENT SYNDROME (ES) AND/OR FLUID OVERLOAD (FO) ASSOCIATED WITH HEMATOPOIETIC STEM CELL TRANSPLANT | OMEROS CORPORATION | 2022-03-03 | — | — | US | disclosed |
| CN-114126642-A | Engineered CD47 extracellular domain for bioconjugation | 小利兰·斯坦福大学托管委员会 | 2022-03-01 | — | — | CN | disclosed |
| US-20210052646-A1 | NUCLEIC-ACID CONTAINING LIPID NANO-PARTICLE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-02-25 | — | — | US | disclosed |
| US-7083952-B2 | Nucleotide sequences coding for proteins involved in the biosynthesis of L-serine, an improved method for the microbial production of L-serine and a genetically modified microorganism suitable therefor | Forschungszentrum Jülich GmbH (DE) | 2006-08-01 | — | — | US | disclosed |
| US-20050165224-A1 | Inhibition of penicillin resistance in s. pneumoniae | ROCKEFELLER UNIVERSITY, THE | 2005-07-28 | — | — | US | disclosed |
| US-20040101837-A1 | Nucleotide sequences coding for proteins involved in the biosynthesis of L-serine, an improved method for the microbial production of L-serine and a genetically modified microorganism suitable therefor | ZIEGLER PETRA (GB) | 2004-05-27 | — | — | US | disclosed |
| WO-2001071038-A1 | INHIBITION OF PENICILLIN RESISTANCE IN S. PNEUMONIAE | THE ROCKEFELLER UNIVERSITY (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035483-A1 | Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and Disorders | CFD, MASP2, C1QBP | MME 113/4885ACE 105/4885CPA1 225/4885 |
| US-20260062499-A1 | Compositions and Methods of Inhibiting MASP-2 for the Treatment of Various Thrombotic Diseases and Disorders | HABP2, CFD, SERPINC1 | MME 1960/4885ACE 415/4885CPA1 907/4885 |
| US-20210052646-A1 | NUCLEIC-ACID CONTAINING LIPID NANO-PARTICLE AND USE THEREOF | NFATC1, NPC1L1, HAVCR2 | MME 1928/4885ACE 2625/4885CPA1 2141/4885 |
| US-20260049158-A1 | Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and Disorders | MASP2, CFD, CFH | MME 106/4885ACE 71/4885CPA1 136/4885 |
| US-20260062498-A1 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | MASP2, C1QBP, C1S | MME 355/4885ACE 265/4885CPA1 142/4885 |
| US-20260078178-A1 | METHODS AND COMPOSITIONS FOR INCREASING IDURONATE 2-SULFATASE ACTIVITY IN THE CNS | IDUA, STS, SLC3A2 | MME 1583/4885ACE 2663/4885CPA1 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.